AI IntelligenceApr 3, 2026Secondary Market
Article
MATN
Matinas BioPharma Holdings filed a notice of delisting or failure to satisfy a continued listing rule (Item 3.01). This indicates potential issues with exchange listing requirements, often leading to significant volatility and negative investor sentiment.
Data Cube AI EditorialSource: SEC EDGAR
01
Source Brief
Matinas BioPharma Holdings filed a notice of delisting or failure to satisfy a continued listing rule (Item 3.01). This indicates potential issues with exchange listing requirements, often leading to significant volatility and negative investor sentiment.
02